Who is sponsoring NCT04643847?

NCT04643847 is sponsored by First People's Hospital of Hangzhou.

What drugs are being tested in NCT04643847?

Interventions in NCT04643847: Almonertinib.

What condition does NCT04643847 study?

NCT04643847 studies EGFR Positive Non-small Cell Lung Cancer, Brain Metastases.

Is NCT04643847 still recruiting?

NCT04643847 is currently status unknown. Last updated 25 November 2020.

Last reviewed 2020-11-25 · How we verify

NCT04643847

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Status unknown Phase 2 Last updated 25 November 2020

What this trial tests

Phase 2 trial testing Almonertinib in EGFR Positive Non-small Cell Lung Cancer in 47 participants. Status unknown.

Timeline

30 November 2020

Primary endpoint
30 November 2022

30 November 2023

Quick facts

Lead sponsor	First People's Hospital of Hangzhou
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	47
Start date	30 November 2020
Primary completion	30 November 2022
Estimated completion	30 November 2023
Sites	1 location across China

Drugs / interventions tested

Almonertinib — full drug profile →

Conditions studied

EGFR Positive Non-small Cell Lung Cancer — all drugs for EGFR Positive Non-small Cell Lung Cancer →
Brain Metastases — all drugs for Brain Metastases →

Sponsor

First People's Hospital of Hangzhou

Who can join

18 and older, any sex, with EGFR Positive Non-small Cell Lung Cancer or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs. This study intends to assess the efficacy and safety of stereotactic radiosurgery with sequential almonertinib in treatment-naive EGFR-mutant NSCLC patients with brain metastases.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases.
Tonse R, Tom MC, Mehta MP, Ahluwalia MS, et al · · 2021 · cited 30× · PMID 34359583 · DOI 10.3390/cancers13153682
Oligometastatic NSCLC: Current Perspectives and Future Challenges.
Torresan S, Costa J, Zanchetta C, De Marchi L, et al · · 2025 · cited 6× · PMID 39996875 · DOI 10.3390/curroncol32020075

Verify or expand the search:

Other trials of Almonertinib

Trials testing the same drug.

NCT06951464 — A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC · Phase 2 · recruiting
NCT05994339 — Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer · Phase 2, PHASE3 · unknown
NCT05768490 — Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastas · Phase 3 · recruiting
NCT05662813 — Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Thera · Phase 2 · unknown
NCT05503888 — Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Ca · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for EGFR Positive Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07322783 — Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification · Phase 2 · recruiting
NCT04900935 — Patient-centered, Optimal Integration of Survivorship and Palliative Care · NA · recruiting

Other First People's Hospital of Hangzhou trials

Trials by the same sponsor.

NCT07507825 — Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) · Phase 2 · not yet recruiting
NCT07390981 — Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder · NA · not yet recruiting
NCT07242443 — Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Py · Phase 4 · not yet recruiting
NCT07207278 — Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma · recruiting
NCT06933992 — Safety and Efficacy of Chocolate Balloon Catheter in Peripheral Arterial Disease (CHOCO-PAD) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04643847 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First People's Hospital of Hangzhou
Last refreshed: 25 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04643847.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing